Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergoogle.com
Google Alert - HER2-ADC
Get the latest updates from Google Alert - HER2-ADC directly as they happen.
Follow now 123 followers
Latest posts
Last updated about 18 hours ago
Shanghai Ailux Biotechnology synthesizes FGFR2-targeting ADCs | BioWorld
about 21 hours ago
An exemplified compound (ADC M15-cu23-B008-AM05-MMAE pg 28) ... Shanghai Ruotuo Biotechnology presents...
BD-200 is strong dual-targeting ADC candidate for cancer | BioWorld
about 22 hours ago
... ADC comparators. In terms of Padcev or enfortumab ADC resistance in...
Choosing First-Line Therapy Among Four FDA-Approved HER2-Directed Options
about 22 hours ago
... HER2-directed ADC. For sevabertinib, SOHO-01 (20 mg twice daily): Cohort D...
Target switching may not be the answer to sequence ADCs in MBC - ESMO Daily Reporter
1 day ago
Similarly poor outcomes were reported in the phase II SATEEN trial of...
Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and ... - OncLive
1 day ago
Rugo notes that while edema is less common with HER2-directed ADCs, profound...
The ovarian cancer drug market - Nature
1 day ago
Discover the world's best science and medicine | Nature.com.
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and ...
3 days ago
... HER2-positive patient-derived cancer model. "We continue to build ... ADC targeting...
HER2CLIMB 02: PFS Benefit Seen With Tucatinib + T DM1 in HER2+ LA/MBC
3 days ago
HER3-DXd shows strong efficacy in ADC-naïve HR+/HER2- metastatic breast cancer, with limited...
HER3-DXd Shows Meaningful Efficacy in ADC‑Naïve HR+/HER2‑ MBC | Docwire News
3 days ago
HER3-DXd shows strong efficacy in ADC-naïve HR+/HER2- metastatic breast cancer, with limited...
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and ...
3 days ago
In the FAP-low/HER2-positive patient derived xenograft model of gastric cancer, durable responses...
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and ...
3 days ago
... HER2-positive patient-derived cancer model. “We continue to build ... ADC targeting...
Callio Therapeutics Highlights Progress of Phase 1 HER2-Targeting ADC Program
4 days ago
The company's LinkedIn post highlights CLIO-8221, a HER2-targeting dual-payload ADC currently in...